Most of us are pretty adept by now at managing COVID-19, with an armor of past infections, vaccinations, self-tests, and antiviral medications like Paxlovid. In the latest study, however ...

Please provide your email address to receive an email when new articles are posted on . Paxlovid may not decrease the risk for hospitalization or death among older adults who are vaccinated.

Follow-up rates were similar in the treated and untreated groups, with slightly more adverse events demonstrated in the Paxlovid vs control group. Researchers conducted a retrospective electronic ...

The commercial transition will begin in November, as the government begins to discontinue the distribution of EUA-labelled Paxlovid. The US will keep an ongoing stockpile of 1 million Paxlovid ...

A study yesterday in JAMA suggests Paxlovid, the oral antiviral approved for use against severe COVID-19 symptoms, did little to lessen the risk of hospitalizations and death among older, vaccinated ...

Prescribing guidelines and the benefits and risks of nirmatrelvir/ritonavir for COVID patients ...

US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant.

During the pandemic,COVID-19 killed more than 7 million people worldwide, including 1.2 million in the U.S. and more than ...

Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read why PFE stock is a Sell.

Paxlovid revenues were also significantly higher ... Also, a one-time contractual delivery to the U.S. Strategic National Stockpile led to sales growth. It remains to be seen if the positive ...